Andere Kunden interessierten sich auch für
![Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic]( "Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic")
Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic60,99 €![Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships]( "Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships")
Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships49,99 €![The Politics of the Opioid Epidemic]( "The Politics of the Opioid Epidemic")
The Politics of the Opioid Epidemic19,99 €![Integrating Clinical Research Into Epidemic Response]( "Integrating Clinical Research Into Epidemic Response")
Integrating Clinical Research Into Epidemic Response90,99 €![Opportunities to Improve Opioid Use Disorder and Infectious Disease Services]( "Opportunities to Improve Opioid Use Disorder and Infectious Disease Services")
Opportunities to Improve Opioid Use Disorder and Infectious Disease Services74,99 €![Framing Opioid Prescribing Guidelines for Acute Pain]( "Framing Opioid Prescribing Guidelines for Acute Pain")
Framing Opioid Prescribing Guidelines for Acute Pain80,99 €![Medications for Opioid Use Disorder Save Lives]( "Medications for Opioid Use Disorder Save Lives")
Medications for Opioid Use Disorder Save Lives63,99 €
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.